Clinical Trial Update: Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221

View source ↗

Summary

Expanded Access Protocol update for glioblastoma patients who already have manufactured DCVax-L and failed screening under protocol 020221; the protocol remains…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• DCVax-L

Snippet

Sponsor: Northwest Biotherapeutics | Conditions: GBM, Glioblastoma Multiforme | Status: AVAILABLE